GE Healthcare Holdings, Inc.

The Agreement, Established as Part of Governor Ron DeSantis' Trade Mission to Italy, Makes Tampa General Hospital the First Health System in the Southeastern United States to Offer Robotic-Assisted Lymphatic Microsurgery. MILAN, Nov. 15, 2024 /PRNewswire/ -- Tampa General Hospital and the University of South Florida announced today an agreement with Medical Microinstruments, Inc., or MMI, to bring the Symani Surgical System, a first-of-its-kind robotic technology, to support lymphatic surgery at TGH. This will be the first and only technology of its kind available in the Southeastern United States and is expected to improve patient outcomes for the most complex procedures involving delicate anatomy. "At Tampa General Hospital, we've invested in the latest technologies and recruited best-in-class providers to make Florida the destination for innovation in health care," said John Couris, president and CEO of Tampa General. "Now, with the support of Governor Ron DeSantis and our state leaders, we're opening doors to new partnerships and introducing more of the world's best technologies in health care to Florida. Because of these efforts, our patients can count on us for world-class care, better outcomes and a higher quality of life." USF President Rhea Law said the agreement with MMI will enhance USF Health and TGH's position as one of the nation's leading academic health systems. "This unique and exciting partnership brings together the very best from both academic medicine and private industry to achieve progress in health care for Floridians who otherwise would not have access to this innovative surgical system in our state," Law said. "We are grateful to Governor DeSantis and our state leaders for their support in helping us improve lives and build a healthier future." "Congratulations to everyone involved in today's MOU signing," said Governor Ron DeSantis. "Florida boasts the best in health care, medical technology, and innovation, and we will continue to support our businesses and hospitals in forging new paths and partnerships. This new robotic surgical technology will increase the quality of life for those battling or recovering from cancer and make procedures for Floridians more precise and less invasive." Charles J. Lockwood, MD, MHCM, executive vice president of USF Health and dean of the USF Health Morsani College of Medicine, said this innovation showcases the strength of academic medicine. "We appreciate that Governor DeSantis and our state legislators understand and support the innovative nature of academic medicine," said Dr. Lockwood, who also serves as executive vice president and chief academic officer at TGH. "Our faculty physicians have the expertise to bring cutting-edge care to our patients in even the most complex cases." The agreement was reached during a trade mission to Italy this week hosted by Florida Governor Ron DeSantis and First Lady Casey DeSantis. President Law formally signed the agreement with MMI during a special ceremony in Italy. Nicholas J. Panetta, M.D., FACS, chief of Tampa General Hospital Plastic Surgery and chair of the Department of Plastic Surgery in the Morsani College of Medicine, and Eduardo M. Sotomayor, M.D., director of the TGH Cancer Institute, also joined the trade mission. MMI's Symani Surgical System uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients and enable more surgeons to perform complex procedures for delicate anatomy. The system features smaller robotic components coupled with enhanced controls so that surgeons can suture tiny vessels and nerves as small as .2 millimeters in diameter. "The problem of cancer-related lymphedema that this collaboration is focused on tackling is significant. Unfortunately, today there is only a handful of surgeons with the skills necessary to treat this often-debilitating condition. The collaboration between MMI, USF and TGH is going to make substantial progress for patients on this front," said Dr. Nicholas Panetta, chief of TGH Plastic Surgery and chair of the Department of Plastic Surgery in the USF Health Morsani College of Medicine. "TGH Cancer Institute is very fortunate to be working with Dr. Panetta's team in building a unique microsurgery and reconstructive oncology program at USF/TGH with a particular focus in breast cancer patients, that would be among the best in the nation and worldwide," said Dr. Sotomayor. MMI's Symani Surgical System is a less invasive surgical treatment for reconstructions and lymphedema. Patients who benefit from the technology experience reduced vessel trauma and require fewer additional procedures. Surgeons who use MMI's Symani Surgical System can accelerate the development of their microsurgical skills and generate higher success rates while reducing adverse events. MMI's Symani Surgical System is just the most recent addition to Tampa General's host of technologies that support minimally invasive surgical procedures. In August, TGH announced the acquisition of the new Intuitive da Vinci 5® Surgical System. Tampa General was the first hospital in the region to offer the new surgical system. ABOUT TAMPA GENERAL HOSPITAL Tampa General Hospital, a 981-bed, not-for-profit, academic health system, is one of the largest hospitals in America and delivers world-class care as the region's only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report's 2024-2025 Best Hospitals, with two medical specialties ranking among the top 20 in the nation and eight medical specialties ranking among the top 50 best hospital programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic health system's commitment to growing and developing its team members is recognized by three prestigious Forbes magazine rankings – in the top 100 nationally in the 2024 America's Best Large Employers, the top 50 in Florida in the 2024 America's Best Employer's by State and the 2023 America's Best Employers for Women, Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2022, provided a net community benefit of approximately $240.3 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It is one of the nation's busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Muma Children's Hospital at TGH, the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital's footprint includes TGH North which is comprised of three hospitals and several outpatient locations in Citrus and Hernando counties, 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Outpatient Center, TGH Virtual Health, and 21 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. For more information, go to . About USF HEALTH USF Health's mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health's multispecialty physicians' group. The University of South Florida is a high-impact global research university dedicated to student success. Over the past 10 years, no other public university in the country has risen faster in U.S. News & World Report's national university rankings than USF. For more information, visit health.usf.edu. Media Contact: Amanda Bevis (202) 680-9262 (cell) [email protected] SOURCE Tampa General Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CHICAGO--( BUSINESS WIRE )--GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS, i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The FDA clearance of SIGNA MAGNUS underscores the advances made by GE HealthCare in neuroimaging. It features an innovative asymmetrical, high-efficiency, head-only gradient coil design, which achieves higher gradient performance due to its reduced inner diameter, specifically tailored for neuroimaging. The asymmetrical design shifts the gradient isocenter to the patient edge of the coil rather than its geometric center, enabling patient head access and avoiding shoulder width constraints. This head-only design allows MAGNUS to deliver a gradient amplitude and slew rate far surpassing those of conventional 60cm or 70cm bore whole-body MRI systems, marking a significant advancement in MRI technology for neuroimaging applications. "Obtaining FDA clearance further validates our commitment to not only innovating but also in delivering clinical technologies that have real-world impact," said Jason Polzin, GM, MR Applications Platform and Research Technologies, GE HealthCare. "With SIGNA MAGNUS, we are providing neuroradiologists and neuroscience researchers a tool that supports advanced imaging and biomarker research and discovery previously impossible on conventional systems. It is our intent to make SIGNA MAGNUS widely available as a fully cleared commercial product." A New Standard for Neuroimaging and Biomarker Discovery SIGNA MAGNUS offers exceptional precision, enabling high-resolution, high signal-to-noise ratio imaging, advanced diffusion techniques, and short scan times. To date, four investigational MAGNUS systems have been installed at Walter Reed National Military Medical Center, University of Iowa, University of Wisconsin – Madison and Brigham and Women’s Hospital. Dr. Vince A. Magnotta, PhD, Director of the MR Research Facility and Professor of Radiology – Division of Neuroradiology, University of Iowa, praised the FDA clearance, stating, "FDA clearance is important because there’s a broad need for new biomarkers to study neurodegenerative disorders, and there’s an opportunity to better understand what’s happening in psychiatric disorders." GE HealthCare has demonstrated leadership in high-performance gradient technology with the introduction of HyperG gradients, one of the most efficient gradient coils on the market ii , in the SIGNA MAGNUS system. The innovative asymmetric head-only design of the HyperG gradient coil invokes significantly less Peripheral Nerve Stimulation (PNS) thus maximizing the actual use of the system’s gradient performance for both clinical and research scanning. The HyperG gradient technology achieves remarkable performance levels of 300 mT/m and 750 T/m/s, enabling faster image acquisition while using the same power requirement as the whole-body SIGNA Premier 3.0T system. Shorter scan times mean less time spent in the MRI machine, which is particularly beneficial for patients who may have difficulty remaining still or those with claustrophobia. Improved gradient strengths lead to enhanced spatial resolution and image clarity. This can result in accurate diagnoses, allowing healthcare providers to detect subtle abnormalities and provide better treatment options. Clinical and Research Excellence The enhanced capabilities of the SIGNA MAGNUS system provide ultra-high anatomical resolution with shorter scan times. Its ability to visualize brain function, microstructure, and micro-vasculature through innovations such as ODEN (Oscillating Gradient Diffusion Encoding) which uses oscillating gradients to provide cellularity contrast which can be important for neurological oncology. Our intention is to leverage the high-gradient performance of SIGNA MAGNUS capabilities to allow for advanced research scanning such as high B-value diffusion imaging, fMRI for investigating the BOLD (Blood Oxygen Level Dependent) response and measurement of slow CSF (Cerebral Spinal Fluid) flow. This marks a transformative step forward in advancing neuroscience research. “We're very excited about the capabilities SIGNA MAGNUS provides,” said Kawin Setsompop, PhD, Associate Professor of Radiology and by courtesy Electrical Engineering, Associate Chair of Research Strategic Development, Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.” SIGNA MAGNUS will be available for both forward production and upgrades from compatible SIGNA Premier systems. This means that existing facilities can upgrade to this advanced technology, expanding access to high-performance imaging without the need for entirely new systems, additional power or cooling. This FDA clearance empowers the clinical community to adopt SIGNA MAGNUS into routine practice and further advances research in critical areas such as neurodegenerative, neuro-oncology and psychiatric disorders. Learn more about SIGNA MAGNUS at the Radiological Society of North America (RSNA) Annual Meeting, December 1–4, 2024, in Chicago, or online at gehealthcare.com . About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on LinkedIn , X , Facebook , Instagram , and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information. i SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions. ii GE HealthCare data on file

GE HealthCare and DeepHealth, a subsidiary of RadNet, announced they are collaborating on new AI imaging technology to further innovation, commercialization and adoption of AI in imaging. The companies will codevelop SmartTechnology, solutions that employ the power of AI to tackle key obstacles across the imaging value chain, such as helping increase the efficiency of imaging interpretation and reporting, allowing collaboration across care teams, improving the clinical interpretation of images and strengthening operational efficiency and productivity. SmartTechnology will unite GE HealthCare’s imaging proficiency and scale capabilities, RadNet’s experience in care delivery and DeepHealth’s AI-enabled health informatics portfolio to improve end-to-end clinical and operational workflows. At the outset, GE HealthCare and RadNet will first work to combine DeepHealth’s AI-based SmartMammo workflow and clinical solution with GE HealthCare’s patient-centric Senographe Pristina mammography system to deliver AI-powered clinical imaging support to breast cancer screening. GE HealthCare’s Senographe Pristina mammography system is used to ease anxiety for the patient in the exam room. The alliance will also allow GE HealthCare to distribute SmartMammo and other DeepHealth solutions to imaging providers in the U.S. as part of GE HealthCare’s extensive portfolio of imaging technologies. "We are thrilled to collaborate with GE HealthCare to accelerate the adoption of AI-powered technologies in radiology," Kees Wesdorp, president and CEO of RadNet’s digital health division, said in a statement. "By combining our pioneering cloud-native operating system, DeepHealth OS and our AI-powered health informatics portfolio with GE HealthCare’s cutting-edge imaging technology, we are poised to revolutionize large-scale diagnostic and screening programs, streamline radiology workflows and improve patient outcomes. This collaboration aims to empower healthcare providers with the tools they need to deliver more effective and personalized care at scale." Roland Rott, president and CEO imaging for GE HealthCare, said the company has a legacy of imaging and AI innovation, and is committed to continued pursuit of new technologies that push the boundaries of what is possible to enable precision care. "This new collaboration with DeepHealth harnesses our combined strengths to address critical challenges in healthcare today," Rott said in a statement. "As we look to make more personalized, patient-centered breast care a reality – AI continues to show great promise in breast cancer screening from early detection and risk prediction, to reduced callbacks and more efficient workflows for breast imaging providers. We are excited to bring the power of imaging and AI together to elevate personalized breast care for those facing this difficult diagnosis." THE LARGER TREND In October, GE HealthCare announced CareIntellect for Oncology, a cloud application that joins multimodal patient data from different systems into a single view with the aid of generative AI to give clinicians access to notes and reports. The application also shows applicable data to help care teams understand disease progression and identify likely deviations from the treatment plan to help clinicians decide probable next steps and inform proactive interventions. The app will initially target prostate and breast cancer. It will be available next year. In July, GE HealthCare and Amazon Web Services (AWS) formed a strategic partnership to use AWS' healthcare and genAI services to build AI workflows to help enhance the accuracy of diagnostic screening, streamline healthcare operations and improve equitable care access and outcomes. GE said that it will use Amazon Bedrock's foundation models to create its own proprietary genAI applications and modernize its applications built on Amazon SageMaker. In June, GE HealthCare and MediView XR announced the first successful clinical use of their codeveloped OmnifyXR Interventional Suite System. OmnifyXR pairs GE's imaging technology with MediView's AR and surgical navigation platform to help physicians better understand a patient's anatomy, make more informed clinical decisions and allow for remote collaboration by care teams in different locations. In 2022, Volpara Health Technologies signed a contract with RadNet to deploy Volpara Analytics and Volpara Risk Pathways software across RadNet's 353 imaging centers in seven U.S. states.